Skip to main content
Top
Published in: Drug Safety 6/2001

01-05-2001 | Review Article

Drug-Induced Lipid Changes

A Review of the Unintended Effects of Some Commonly Used Drugs on Serum Lipid Levels

Authors: Dr Aukje K. Mantel-Teeuwisse, Judith M.E. Kloosterman, Anke Hilse Maitland- van der Zee, Olaf H. Klungel, Arijan J. Porsius, Anthonius de Boer

Published in: Drug Safety | Issue 6/2001

Login to get access

Abstract

Many drugs besides lipid-lowering drugs affect serum lipid levels in either a potentially harmful or beneficial way, and may therefore increase or decrease the risk of cardiovascular disease.
Diuretics, β-blocking agents, progestogens, combined oral contraceptives containing ‘second generation’ progestogens, danazol, immunosuppressive agents, protease inhibitors and enzyme-inducing anticonvulsants adversely affect the lipid profile. They increase total cholesterol, low density lipoprotein cholesterol and triglycerides by up to 40, 50 and 300%, respectively, and decrease high density lipoprotein cholesterol by a maximum of 50%. Conversely, α-blocking agents, estrogens, hormone replacement therapy, combined oral contraceptives containing ‘third generation’ progestogens, selective estrogen receptor modulators, growth hormone and valproic acid show mostly beneficial effects on the lipd profile. Some drugs, for example, isotretinoin, acitretin and antipsychotics, mainly elevate triglyceride levels.
Adverse or beneficial effects on serum cholesterol levels do not always translate into a higher or lower, respectively, incidence of cardiovascular disease, because these drugs may influence cardiovascular risk through multiple pathways. In some cases, excessive cholesterol levels occur, for example, with protease inhibitor therapy, and several cases of pancreatitis attributable to drug-induced hypertriglyceridaemia have been reported.
Some general guidelines on the management of drug-induced dyslipidaemia can be given. Replacement of the dyslipidaemia-inducing drug by an equivalent alternative therapy is preferred. However, such alternatives are often difficult to find. If there is no equivalent alternative and treatment with the dyslipidaemia-inducing drug must be initiated, monitoring of serum lipid levels is important. If drug use is expected to be long term, the existing guidelines for the management of dyslipidaemia in the general population can be applied to drug-induced dyslipidaemia. In cases of extreme hyperlipidaemia, medication use should be reassessed.
Literature
1.
go back to reference Kasiske BL, Ma JZ, Kalil RSN, et al. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122: 133–41PubMed Kasiske BL, Ma JZ, Kalil RSN, et al. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122: 133–41PubMed
2.
3.
go back to reference Hunninghake DB. Effects of celiprolol and other antihypertensive agents on serum lipids and lipoproteins. Am Heart J 1991; 121: 696–701PubMedCrossRef Hunninghake DB. Effects of celiprolol and other antihypertensive agents on serum lipids and lipoproteins. Am Heart J 1991; 121: 696–701PubMedCrossRef
4.
go back to reference Weidmann P, de Courten M, Ferrari P. Effects of diuretics on the plasma lipid profile. Eur Heart J 1992; 13: 61G–7GCrossRef Weidmann P, de Courten M, Ferrari P. Effects of diuretics on the plasma lipid profile. Eur Heart J 1992; 13: 61G–7GCrossRef
5.
go back to reference Ames RP. A comparison of blood lipid and blood pressure response during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol 1996; 77: 12B–6BPubMedCrossRef Ames RP. A comparison of blood lipid and blood pressure response during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol 1996; 77: 12B–6BPubMedCrossRef
6.
go back to reference Grimm RH, Flack, JM, Grandits GA, et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA 1996; 275: 1549–56PubMedCrossRef Grimm RH, Flack, JM, Grandits GA, et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA 1996; 275: 1549–56PubMedCrossRef
7.
go back to reference Lakshman MR, Reda DJ, Materson BJ, et al. Diuretics and pblockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Arch Intern Med 1999; 159: 551–8PubMedCrossRef Lakshman MR, Reda DJ, Materson BJ, et al. Diuretics and pblockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Arch Intern Med 1999; 159: 551–8PubMedCrossRef
8.
go back to reference Lind L, Berne C, Pollare T, et al. Metabolic effects of anti-hypertensive treatment with nifedipine or furosemide: a double-blind, cross-over study. J Hum Hypertens 1995; 9: 137–41PubMed Lind L, Berne C, Pollare T, et al. Metabolic effects of anti-hypertensive treatment with nifedipine or furosemide: a double-blind, cross-over study. J Hum Hypertens 1995; 9: 137–41PubMed
9.
go back to reference van der Heijden M, Donders SH, Cleophas TJ, et al. A randomized, placebo-controlled study of loop diuretics in patients with essential hypertension: the bumetanide and furosemide on lipid profile (BUFUL) clinical study report. J Clin Pharmacol 1998; 38: 630–5PubMed van der Heijden M, Donders SH, Cleophas TJ, et al. A randomized, placebo-controlled study of loop diuretics in patients with essential hypertension: the bumetanide and furosemide on lipid profile (BUFUL) clinical study report. J Clin Pharmacol 1998; 38: 630–5PubMed
10.
go back to reference Campbell N, Brant R, Stalts H, et al. Fluctuations in blood lipid levels during furosemide therapy: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med 1998; 158: 1461–3PubMedCrossRef Campbell N, Brant R, Stalts H, et al. Fluctuations in blood lipid levels during furosemide therapy: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med 1998; 158: 1461–3PubMedCrossRef
11.
go back to reference Ambrosioni E, Safar M, Degaute JP, et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European Study Group. J Hypertens 1998; 16: 1677–84PubMedCrossRef Ambrosioni E, Safar M, Degaute JP, et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European Study Group. J Hypertens 1998; 16: 1677–84PubMedCrossRef
12.
go back to reference Howes LG, Lykos D, Rennie GC. Effects of antihypertensive drugs on coronary artery disease risk: a meta analysis. Clin Exp Pharmacol Physiol 1996; 23: 555–8PubMedCrossRef Howes LG, Lykos D, Rennie GC. Effects of antihypertensive drugs on coronary artery disease risk: a meta analysis. Clin Exp Pharmacol Physiol 1996; 23: 555–8PubMedCrossRef
13.
go back to reference Fogari R, Zoppi A, Corradi L, et al. Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 1999; 33: 534–9PubMedCrossRef Fogari R, Zoppi A, Corradi L, et al. Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 1999; 33: 534–9PubMedCrossRef
14.
go back to reference Ravid M, Neumann L, Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int 1995; 47: 907–10PubMedCrossRef Ravid M, Neumann L, Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int 1995; 47: 907–10PubMedCrossRef
15.
go back to reference Hense HW, Doring A, Stieber J, et al. The association of antihypertensive treatment patterns and adverse lipid effects in population-based studies. J Clin Epidemiol 1992; 45: 1423–30PubMedCrossRef Hense HW, Doring A, Stieber J, et al. The association of antihypertensive treatment patterns and adverse lipid effects in population-based studies. J Clin Epidemiol 1992; 45: 1423–30PubMedCrossRef
16.
go back to reference Strickland D, Sprafka JM, Luepker RV, et al. Association of antihypertensive agents and blood lipids in a population- based survey. Epidemiology 1994; 5: 96–101PubMedCrossRef Strickland D, Sprafka JM, Luepker RV, et al. Association of antihypertensive agents and blood lipids in a population- based survey. Epidemiology 1994; 5: 96–101PubMedCrossRef
17.
go back to reference Helmert U, Shea S. Antihypertensive treatment and serum cholesterol: results of population-based surveys in the German Cardiovascular Prevention Study. Rev Environ Health 1997; 12: 253–60PubMed Helmert U, Shea S. Antihypertensive treatment and serum cholesterol: results of population-based surveys in the German Cardiovascular Prevention Study. Rev Environ Health 1997; 12: 253–60PubMed
18.
go back to reference Goode GK, Miller JP, Heagerty AM. Hyperlipidaemia, hypertension, and coronary heart disease. Lancet 1995; 345: 362–4PubMedCrossRef Goode GK, Miller JP, Heagerty AM. Hyperlipidaemia, hypertension, and coronary heart disease. Lancet 1995; 345: 362–4PubMedCrossRef
19.
go back to reference Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277: 739–45PubMedCrossRef Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277: 739–45PubMedCrossRef
20.
go back to reference UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk ofmacrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:713–20 UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk ofmacrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:713–20
21.
go back to reference ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283: 1967–75 ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283: 1967–75
22.
go back to reference Rijpkema AH, van der Sanden AA, Ruijs AH. Effects of postmenopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas 1990; 12: 259–85PubMedCrossRef Rijpkema AH, van der Sanden AA, Ruijs AH. Effects of postmenopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas 1990; 12: 259–85PubMedCrossRef
23.
go back to reference Miller VT, Muesing RA, LaRosa JC, et al. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-I. Obstet Gynecol 1991; 77: 235–40PubMedCrossRef Miller VT, Muesing RA, LaRosa JC, et al. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-I. Obstet Gynecol 1991; 77: 235–40PubMedCrossRef
24.
go back to reference Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196–204PubMedCrossRef Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196–204PubMedCrossRef
25.
go back to reference Lobo RA, Pickar JH, Wild RA, et al. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The Menopause Study Group. Obstet Gynecol 1994; 84: 987–95PubMed Lobo RA, Pickar JH, Wild RA, et al. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The Menopause Study Group. Obstet Gynecol 1994; 84: 987–95PubMed
26.
go back to reference The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial [published erratum appears in JAMA 1995; 274: 1676]. JAMA 1995; 273: 199–208 The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial [published erratum appears in JAMA 1995; 274: 1676]. JAMA 1995; 273: 199–208
27.
go back to reference Mc Manus J, Mc Eneny J, Thompson W, et al. The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women. Atherosclerosis 1997; 135: 73–81CrossRef Mc Manus J, Mc Eneny J, Thompson W, et al. The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women. Atherosclerosis 1997; 135: 73–81CrossRef
28.
go back to reference Baker VL. Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery. Obstet Gynecol Clin North Am 1994; 21: 271–97PubMed Baker VL. Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery. Obstet Gynecol Clin North Am 1994; 21: 271–97PubMed
29.
go back to reference Moorjani S, Dupont A, Labrie F, et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metab 1991; 73: 373–9PubMedCrossRef Moorjani S, Dupont A, Labrie F, et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metab 1991; 73: 373–9PubMedCrossRef
30.
go back to reference Silfverstolpe G, Gustafson A, Samsioe G, et al. Lipid metabolic studies in oophorectomized women: effects of three different progestogens. Acta Obstet Gynecol Scand 1979; 88Suppl.: S89–S95CrossRef Silfverstolpe G, Gustafson A, Samsioe G, et al. Lipid metabolic studies in oophorectomized women: effects of three different progestogens. Acta Obstet Gynecol Scand 1979; 88Suppl.: S89–S95CrossRef
31.
go back to reference Saarikoski S, Yliskoski M, Penttila I. Sequential use of norethisterone and natural progesterone in pre-menopausal bleeding disorders. Maturitas 1990; 12: 89–97PubMedCrossRef Saarikoski S, Yliskoski M, Penttila I. Sequential use of norethisterone and natural progesterone in pre-menopausal bleeding disorders. Maturitas 1990; 12: 89–97PubMedCrossRef
32.
go back to reference Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323: 1375–81PubMedCrossRef Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323: 1375–81PubMedCrossRef
33.
go back to reference Ball MJ, Ashwell E, Gillmer MD. Progestagen-only oral contraceptives: comparison of the metabolic effects of levonorgestrel and norethisterone. Contraception 1991; 44: 223–33PubMedCrossRef Ball MJ, Ashwell E, Gillmer MD. Progestagen-only oral contraceptives: comparison of the metabolic effects of levonorgestrel and norethisterone. Contraception 1991; 44: 223–33PubMedCrossRef
34.
go back to reference Enk L, Landgren BM, Lindberg UB, et al. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Horm Metab Res 1992; 24: 85–9PubMedCrossRef Enk L, Landgren BM, Lindberg UB, et al. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Horm Metab Res 1992; 24: 85–9PubMedCrossRef
35.
go back to reference McEwan JA, Griffin M, Fotherby K, et al. Long-term use of depot-norethisterone enanthate: effect on blood lipid fractions. Contraception 1992; 46: 49–60PubMedCrossRef McEwan JA, Griffin M, Fotherby K, et al. Long-term use of depot-norethisterone enanthate: effect on blood lipid fractions. Contraception 1992; 46: 49–60PubMedCrossRef
36.
go back to reference Fahmy K, Khairy M, Allam G, et al. Effect of depo-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women. Contraception 1991; 44: 431–44PubMedCrossRef Fahmy K, Khairy M, Allam G, et al. Effect of depo-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women. Contraception 1991; 44: 431–44PubMedCrossRef
37.
go back to reference Garza-Flores J, De la Cruz DL, Valles de Bourges V, et al. Longterm effects of depot-medroxyprogesterone acetate on lipoprotein metabolism. Contraception 1991; 44: 61–71PubMedCrossRef Garza-Flores J, De la Cruz DL, Valles de Bourges V, et al. Longterm effects of depot-medroxyprogesterone acetate on lipoprotein metabolism. Contraception 1991; 44: 61–71PubMedCrossRef
38.
go back to reference Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47–63PubMedCrossRef Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47–63PubMedCrossRef
39.
40.
go back to reference Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–13PubMedCrossRef Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–13PubMedCrossRef
41.
go back to reference Kafrissen ME, Corson SL. Comparative review of third-generation progestins. Int J Fertil 1992; 37Suppl. 2: 104–15PubMed Kafrissen ME, Corson SL. Comparative review of third-generation progestins. Int J Fertil 1992; 37Suppl. 2: 104–15PubMed
42.
go back to reference Speroff L, DeCherney A. Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins. Obstet Gynecol 1993; 81: 1034–47PubMed Speroff L, DeCherney A. Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins. Obstet Gynecol 1993; 81: 1034–47PubMed
43.
go back to reference Lobo RA, Skinner JB, Lippman JS, et al. Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis. Fertil Steril 1996; 65: 1100–9PubMed Lobo RA, Skinner JB, Lippman JS, et al. Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis. Fertil Steril 1996; 65: 1100–9PubMed
44.
go back to reference Crook D, Godsland I. Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism [published erratum appears in Contraception 1998; 57: 420]. Contraception 1998; 57: 189–201PubMedCrossRef Crook D, Godsland I. Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism [published erratum appears in Contraception 1998; 57: 420]. Contraception 1998; 57: 189–201PubMedCrossRef
45.
go back to reference Burkman RT, Robinson JC, Kruszon-Moran D, et al. Lipid and lipoprotein changes associated with oral contraceptive use: a randomized clinical trial. Obstet Gynecol 1988; 71: 33–8PubMed Burkman RT, Robinson JC, Kruszon-Moran D, et al. Lipid and lipoprotein changes associated with oral contraceptive use: a randomized clinical trial. Obstet Gynecol 1988; 71: 33–8PubMed
46.
go back to reference Burkman RT, Zacur HA, Kimball AW, et al. Oral contraceptives and lipids and lipoproteins: part I — variations in mean levels by oral contraceptive type. Contraception 1989; 40: 553–61PubMedCrossRef Burkman RT, Zacur HA, Kimball AW, et al. Oral contraceptives and lipids and lipoproteins: part I — variations in mean levels by oral contraceptive type. Contraception 1989; 40: 553–61PubMedCrossRef
47.
go back to reference Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589–93PubMedCrossRef Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589–93PubMedCrossRef
48.
go back to reference Hannaford PC, Owen-Smith V. Using epidemiological data to guide clinical practice: review of studies on cardiovascular disease and use of combined oral contraceptives. BMJ 1998; 316: 984–7PubMedCrossRef Hannaford PC, Owen-Smith V. Using epidemiological data to guide clinical practice: review of studies on cardiovascular disease and use of combined oral contraceptives. BMJ 1998; 316: 984–7PubMedCrossRef
49.
go back to reference Hannaford P. Cardiovascular events associated with different combined oral contraceptives: a review of current data. Drug Saf 2000; 22: 361–71PubMedCrossRef Hannaford P. Cardiovascular events associated with different combined oral contraceptives: a review of current data. Drug Saf 2000; 22: 361–71PubMedCrossRef
50.
go back to reference Herings RM, Urquhart J, Leufkens HG. Venous thromboembolism among new users of different oral contraceptives [published erratum appears in Lancet 1999 Oct 23; 354 (9188): 1478]. Lancet 1999; 354: 127–8PubMedCrossRef Herings RM, Urquhart J, Leufkens HG. Venous thromboembolism among new users of different oral contraceptives [published erratum appears in Lancet 1999 Oct 23; 354 (9188): 1478]. Lancet 1999; 354: 127–8PubMedCrossRef
51.
go back to reference Benshushan A, Brzezinski A. Tamoxifen effects on menopause-associated risk factors and symptoms. Obstet Gynecol Surv 1999; 54: 272–8PubMedCrossRef Benshushan A, Brzezinski A. Tamoxifen effects on menopause-associated risk factors and symptoms. Obstet Gynecol Surv 1999; 54: 272–8PubMedCrossRef
52.
go back to reference McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 1991; 303: 435–7PubMedCrossRef McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 1991; 303: 435–7PubMedCrossRef
53.
go back to reference Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993; 85: 1398–406PubMedCrossRef Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993; 85: 1398–406PubMedCrossRef
54.
go back to reference Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996; 11: 835–42PubMedCrossRef Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996; 11: 835–42PubMedCrossRef
55.
go back to reference Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641–7PubMedCrossRef Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641–7PubMedCrossRef
56.
go back to reference Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445–51PubMedCrossRef Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445–51PubMedCrossRef
57.
go back to reference Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998; 13: 1747–54PubMedCrossRef Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998; 13: 1747–54PubMedCrossRef
58.
go back to reference de Valk-de Roo GW, Stehouwer CD, Meijer P, et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 1999; 19: 2993–3000PubMedCrossRef de Valk-de Roo GW, Stehouwer CD, Meijer P, et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 1999; 19: 2993–3000PubMedCrossRef
59.
go back to reference Packard CJ, Shepherd J. Action of danazol on plasma lipids and lipoprotein metabolism. Acta Obstet Gynecol Scand 1994; 159Suppl.: 35–40 Packard CJ, Shepherd J. Action of danazol on plasma lipids and lipoprotein metabolism. Acta Obstet Gynecol Scand 1994; 159Suppl.: 35–40
60.
go back to reference Rosen T, Johannsson G, Johansson JO, et al. Consequences of growth hormone deficiency in adults and the benefits and risks of recombinant human growth hormone treatment: a review paper. Horm Res 1995; 43: 93–9PubMedCrossRef Rosen T, Johannsson G, Johansson JO, et al. Consequences of growth hormone deficiency in adults and the benefits and risks of recombinant human growth hormone treatment: a review paper. Horm Res 1995; 43: 93–9PubMedCrossRef
61.
go back to reference Cuneo RC, Salomon F, Watts GF, et al. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 1993; 42: 1519–23PubMedCrossRef Cuneo RC, Salomon F, Watts GF, et al. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 1993; 42: 1519–23PubMedCrossRef
62.
go back to reference Russell-Jones DL, Watts GF, Weissberger A, et al. The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clin Endocrinol Oxf 1994; 41: 345–50PubMedCrossRef Russell-Jones DL, Watts GF, Weissberger A, et al. The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clin Endocrinol Oxf 1994; 41: 345–50PubMedCrossRef
63.
go back to reference Johannsson G, Oscarsson J, Rosen T, et al. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults: influence of gender and Apo(a) and ApoE phenotypes. Arterioscler Thromb Vasc Biol 1995; 15: 2142–50PubMedCrossRef Johannsson G, Oscarsson J, Rosen T, et al. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults: influence of gender and Apo(a) and ApoE phenotypes. Arterioscler Thromb Vasc Biol 1995; 15: 2142–50PubMedCrossRef
64.
go back to reference Leese GP, Wallymahmed M, VanHeyningen C, et al. HDL-cholesterol reductions associated with adult growth hormone replacement. Clin Endocrinol Oxf 1998; 49: 673–7PubMedCrossRef Leese GP, Wallymahmed M, VanHeyningen C, et al. HDL-cholesterol reductions associated with adult growth hormone replacement. Clin Endocrinol Oxf 1998; 49: 673–7PubMedCrossRef
65.
go back to reference Leese GP, Wallymahmed M, Wieringa G, et al. Apo E phenotype and changes in serum lipids in adult patients during growth hormone replacement. Eur J Endocrinol 1999; 140: 174–9PubMedCrossRef Leese GP, Wallymahmed M, Wieringa G, et al. Apo E phenotype and changes in serum lipids in adult patients during growth hormone replacement. Eur J Endocrinol 1999; 140: 174–9PubMedCrossRef
66.
go back to reference Lyons F, Laker MF, Marsden JR, et al. Effect of oral 13-cisretinoic acid on serum lipids. Br J Dermatol 1982; 107: 591–5PubMedCrossRef Lyons F, Laker MF, Marsden JR, et al. Effect of oral 13-cisretinoic acid on serum lipids. Br J Dermatol 1982; 107: 591–5PubMedCrossRef
67.
go back to reference Zech LA, Gross EG, Peck GL, et al. Changes in plasma cholesterol and triglyceride levels after treatment with oral isotretinoin: a prospective study. Arch Dermatol 1983; 119: 987–93PubMedCrossRef Zech LA, Gross EG, Peck GL, et al. Changes in plasma cholesterol and triglyceride levels after treatment with oral isotretinoin: a prospective study. Arch Dermatol 1983; 119: 987–93PubMedCrossRef
68.
go back to reference Bershad S, Rubinstein A, Paterniti JR, et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med 1985; 313: 981–5PubMedCrossRef Bershad S, Rubinstein A, Paterniti JR, et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med 1985; 313: 981–5PubMedCrossRef
69.
go back to reference Melnik BC, Bros U, Plewig G. Evaluation of the atherogenic risk of isotretinoin-induced and etretinate-induced alterations of lipoprotein cholesterol metabolism. J Invest Dermatol 1987; 88Suppl. 3: S39–S43CrossRef Melnik BC, Bros U, Plewig G. Evaluation of the atherogenic risk of isotretinoin-induced and etretinate-induced alterations of lipoprotein cholesterol metabolism. J Invest Dermatol 1987; 88Suppl. 3: S39–S43CrossRef
70.
go back to reference Walker BR, MacKie RM. Serum lipid elevation during isotretinoin therapy for acne in the west of Scotland. Br J Dermatol 1990; 122: 531–7PubMedCrossRef Walker BR, MacKie RM. Serum lipid elevation during isotretinoin therapy for acne in the west of Scotland. Br J Dermatol 1990; 122: 531–7PubMedCrossRef
71.
go back to reference Barth JH, Macdonald-Hull SP, Mark J, et al. Isotretinoin therapy for acne vulgaris: a re-evaluation of the need for measurements of plasma lipids and liver function tests. Br J Dermatol 1993; 129: 704–7PubMedCrossRef Barth JH, Macdonald-Hull SP, Mark J, et al. Isotretinoin therapy for acne vulgaris: a re-evaluation of the need for measurements of plasma lipids and liver function tests. Br J Dermatol 1993; 129: 704–7PubMedCrossRef
72.
go back to reference Fex GA, Aronsson A, Andersson A, et al. In vivo effects of 13-cis retinoic acid treatment on the concentration of proteins and lipids in serum. Eur J Clin Chem Clin Biochem 1996; 34: 3–7PubMed Fex GA, Aronsson A, Andersson A, et al. In vivo effects of 13-cis retinoic acid treatment on the concentration of proteins and lipids in serum. Eur J Clin Chem Clin Biochem 1996; 34: 3–7PubMed
73.
go back to reference Lestringant GG, Frossard PM, Agarwal M, et al. Variations in lipid and lipoprotein levels during isotretinoin treatment for acne vulgaris with special emphasis on HDL-cholesterol. Int J Dermatol 1997; 36: 859–62PubMedCrossRef Lestringant GG, Frossard PM, Agarwal M, et al. Variations in lipid and lipoprotein levels during isotretinoin treatment for acne vulgaris with special emphasis on HDL-cholesterol. Int J Dermatol 1997; 36: 859–62PubMedCrossRef
74.
go back to reference Neele DM, Buytenhek R, Staels B, et al. No short-term effect of oral isotretinoin (13-cis retinoic acid) on lipoprotein(a) and HDL subclasses LP-A-I and LP-A-I: A-II in healthy volunteers. J Intern Med 1999; 246: 120–2PubMedCrossRef Neele DM, Buytenhek R, Staels B, et al. No short-term effect of oral isotretinoin (13-cis retinoic acid) on lipoprotein(a) and HDL subclasses LP-A-I and LP-A-I: A-II in healthy volunteers. J Intern Med 1999; 246: 120–2PubMedCrossRef
75.
go back to reference Vahlquist C, Selinus I, Vessby B. Serum lipid changes during acitretin (etretin) treatment of psoriasis and palmo-plantar pustulosis. Acta Derm Venereol 1988; 68: 300–5PubMed Vahlquist C, Selinus I, Vessby B. Serum lipid changes during acitretin (etretin) treatment of psoriasis and palmo-plantar pustulosis. Acta Derm Venereol 1988; 68: 300–5PubMed
76.
go back to reference Olsen EA, Weed WW, Meyer CJ, et al. Adouble-blind, placebocontrolled trial of acitretin for the treatment of psoriasis. J Am Acad Dermatol 1989; 21: 681–6PubMedCrossRef Olsen EA, Weed WW, Meyer CJ, et al. Adouble-blind, placebocontrolled trial of acitretin for the treatment of psoriasis. J Am Acad Dermatol 1989; 21: 681–6PubMedCrossRef
77.
go back to reference Gupta AK, Goldfarb MT, Ellis CN, et al. Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 1989; 20: 1088–93PubMedCrossRef Gupta AK, Goldfarb MT, Ellis CN, et al. Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 1989; 20: 1088–93PubMedCrossRef
78.
go back to reference Frati C, Bevilacqua L, Apostolico V. Association of etretinate and fish oil in psoriasis therapy: inhibition of hypertriglyceridemia resulting from retinoid therapy after fish oil supplementation. Acta Derm Venereol 1994; 186Suppl.: 151–3 Frati C, Bevilacqua L, Apostolico V. Association of etretinate and fish oil in psoriasis therapy: inhibition of hypertriglyceridemia resulting from retinoid therapy after fish oil supplementation. Acta Derm Venereol 1994; 186Suppl.: 151–3
79.
go back to reference Vahlquist C, Olsson AG, Lindholm A, et al. Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients: results of a double-blind cross-over study. Acta Derm Venereol 1995; 5: 377–80 Vahlquist C, Olsson AG, Lindholm A, et al. Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients: results of a double-blind cross-over study. Acta Derm Venereol 1995; 5: 377–80
80.
go back to reference Omenn GS, Goodman G, Thornquist M, et al. The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. Cancer Res 1994; 54Suppl. 7: S2038–S43 Omenn GS, Goodman G, Thornquist M, et al. The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. Cancer Res 1994; 54Suppl. 7: S2038–S43
81.
go back to reference Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150–5PubMedCrossRef Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150–5PubMedCrossRef
82.
go back to reference Redlich CA, Chung JS, Cullen MR, et al. Effect of long-term beta-carotene and vitamin Aon serum cholesterol and triglyceride levels among participants in the Carotene and Retinol Efficacy Trial (CARET) [corrected and republished article originally printed in Atherosclerosis 1999 Apr; 143 (2): 427-34]. Atherosclerosis 1999; 145: 425–32PubMedCrossRef Redlich CA, Chung JS, Cullen MR, et al. Effect of long-term beta-carotene and vitamin Aon serum cholesterol and triglyceride levels among participants in the Carotene and Retinol Efficacy Trial (CARET) [corrected and republished article originally printed in Atherosclerosis 1999 Apr; 143 (2): 427-34]. Atherosclerosis 1999; 145: 425–32PubMedCrossRef
83.
go back to reference Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621–7PubMedCrossRef Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621–7PubMedCrossRef
84.
go back to reference Brown JH, Murphy BG, Douglas AF, et al. Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. Nephron 1997; 75: 277–82PubMedCrossRef Brown JH, Murphy BG, Douglas AF, et al. Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. Nephron 1997; 75: 277–82PubMedCrossRef
85.
go back to reference Lippuner K, Casez JP, Horber FF, et al. Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients. J Clin Endocrinol Metab 1998; 83: 3795–802PubMedCrossRef Lippuner K, Casez JP, Horber FF, et al. Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients. J Clin Endocrinol Metab 1998; 83: 3795–802PubMedCrossRef
86.
go back to reference Quaschning T, Mainka T, Nauck M, et al. Immunosuppression enhances atherogenicity of lipid profile after transplantation. Kidney Int 1999; 71Suppl.: S235–S7CrossRef Quaschning T, Mainka T, Nauck M, et al. Immunosuppression enhances atherogenicity of lipid profile after transplantation. Kidney Int 1999; 71Suppl.: S235–S7CrossRef
87.
go back to reference Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18: 336–45PubMedCrossRef Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18: 336–45PubMedCrossRef
88.
go back to reference Meffert H, Brautigam M, Farber L, et al. Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile. Acta Derm Venereol 1997; 77: 137–41PubMed Meffert H, Brautigam M, Farber L, et al. Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile. Acta Derm Venereol 1997; 77: 137–41PubMed
89.
go back to reference Simmons WD, Rayhill SC, Sollinger HW. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf 1997; 17: 75–92PubMedCrossRef Simmons WD, Rayhill SC, Sollinger HW. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf 1997; 17: 75–92PubMedCrossRef
90.
go back to reference Brattstrom C, Wilczek H, Tyden G, et al. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998; 65: 1272–4PubMedCrossRef Brattstrom C, Wilczek H, Tyden G, et al. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998; 65: 1272–4PubMedCrossRef
91.
go back to reference Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040–6PubMedCrossRef Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040–6PubMedCrossRef
92.
go back to reference Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036–42PubMedCrossRef Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036–42PubMedCrossRef
93.
go back to reference Wanner C, Bartens W, Galle J. Clinical utility of antilipidemic therapies in chronic renal allograft failure. Kidney Int 1995; 52 Suppl.: S60–S2 Wanner C, Bartens W, Galle J. Clinical utility of antilipidemic therapies in chronic renal allograft failure. Kidney Int 1995; 52 Suppl.: S60–S2
94.
go back to reference Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1–34PubMedCrossRef Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1–34PubMedCrossRef
95.
go back to reference Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093–9PubMedCrossRef Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093–9PubMedCrossRef
96.
go back to reference Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51–F8PubMedCrossRef Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51–F8PubMedCrossRef
97.
go back to reference _Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995; 333: 1528–33PubMedCrossRef _Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995; 333: 1528–33PubMedCrossRef
98.
go back to reference Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995; 333: 1534–9PubMed Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995; 333: 1534–9PubMed
99.
go back to reference Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100: 700–5PubMedCrossRef Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100: 700–5PubMedCrossRef
100.
go back to reference Roberts AD, Muesing RA, Parenti DM, et al. Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients. Clin Infect Dis 1999; 29: 441–3PubMedCrossRef Roberts AD, Muesing RA, Parenti DM, et al. Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients. Clin Infect Dis 1999; 29: 441–3PubMedCrossRef
101.
go back to reference Berthold HK, Parhofer KG, Ritter MM, et al. Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med 1999; 246: 567–75PubMedCrossRef Berthold HK, Parhofer KG, Ritter MM, et al. Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med 1999; 246: 567–75PubMedCrossRef
102.
103.
go back to reference Echevarria KL, Hardin TC, Smith JA. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother 1999; 33: 859–63PubMedCrossRef Echevarria KL, Hardin TC, Smith JA. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother 1999; 33: 859–63PubMedCrossRef
104.
go back to reference Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351: 1328PubMedCrossRef Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351: 1328PubMedCrossRef
105.
go back to reference Behrens G, Schmidt H, Meyer D, et al. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998; 351: 1958PubMedCrossRef Behrens G, Schmidt H, Meyer D, et al. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998; 351: 1958PubMedCrossRef
106.
go back to reference Karmochkine M, Raguin G. Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir. AIDS 1998; 12: 2499PubMed Karmochkine M, Raguin G. Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir. AIDS 1998; 12: 2499PubMed
107.
go back to reference Stricker RB, Man KM, Bouvier DB, et al. Pancreatorenal syndrome associated with combination antiretroviral therapy in HIV infection. Lancet 1997; 349: 1745–6PubMedCrossRef Stricker RB, Man KM, Bouvier DB, et al. Pancreatorenal syndrome associated with combination antiretroviral therapy in HIV infection. Lancet 1997; 349: 1745–6PubMedCrossRef
108.
go back to reference Mirete G, Masia M, Gutierrez F, et al. Acute pancreatitis as a complication of ritonavir therapy in a patient with AIDS. Eur J Clin Microbiol Infect Dis 1998; 17: 810–1PubMedCrossRef Mirete G, Masia M, Gutierrez F, et al. Acute pancreatitis as a complication of ritonavir therapy in a patient with AIDS. Eur J Clin Microbiol Infect Dis 1998; 17: 810–1PubMedCrossRef
109.
go back to reference Di Martino V, Ezenfis J, Benhamou Y, et al. Severe acute pancreatitis related to the use of nelfinavir in HIV infection: report of a case with positive rechallenge. Aids 1999; 13: 1421–3PubMedCrossRef Di Martino V, Ezenfis J, Benhamou Y, et al. Severe acute pancreatitis related to the use of nelfinavir in HIV infection: report of a case with positive rechallenge. Aids 1999; 13: 1421–3PubMedCrossRef
110.
go back to reference Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13: 805–10PubMedCrossRef Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13: 805–10PubMedCrossRef
111.
go back to reference Wierzbicki AS, Reynolds TM, Crook MA, et al. Lipid lowering therapy in patients with HIV infection. Lancet 1998; 352: 1782PubMedCrossRef Wierzbicki AS, Reynolds TM, Crook MA, et al. Lipid lowering therapy in patients with HIV infection. Lancet 1998; 352: 1782PubMedCrossRef
112.
go back to reference Dube MP, Sprecher D, Henry WK, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000; 31: 1216–24PubMedCrossRef Dube MP, Sprecher D, Henry WK, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000; 31: 1216–24PubMedCrossRef
113.
go back to reference Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999; 156: 1270–2PubMed Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999; 156: 1270–2PubMed
114.
go back to reference Sasaki J, Funakoshi M, Arakawa K. Lipids and apolipoproteins in patients treated with major tranquilizers. Clin Pharmacol Ther 1985; 37: 684–7PubMedCrossRef Sasaki J, Funakoshi M, Arakawa K. Lipids and apolipoproteins in patients treated with major tranquilizers. Clin Pharmacol Ther 1985; 37: 684–7PubMedCrossRef
115.
go back to reference Hussar AE. Coronary heart disease in chronic schizophrenic patients: aclinicopathologic study. Circulation 1965; 31: 919–29PubMedCrossRef Hussar AE. Coronary heart disease in chronic schizophrenic patients: aclinicopathologic study. Circulation 1965; 31: 919–29PubMedCrossRef
116.
go back to reference Bergemann N, Ehrig C, Diebold K, et al. Asymptomatic pancreatitis associated with clozapine. Pharmacopsychiatry 1999; 32: 78–80PubMedCrossRef Bergemann N, Ehrig C, Diebold K, et al. Asymptomatic pancreatitis associated with clozapine. Pharmacopsychiatry 1999; 32: 78–80PubMedCrossRef
117.
go back to reference Calandre EP, Rodriquez-Lopez C, Blazquez A, et al. Serum lipids, lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital. Acta Neurol Scand 1991; 83: 250–3PubMedCrossRef Calandre EP, Rodriquez-Lopez C, Blazquez A, et al. Serum lipids, lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital. Acta Neurol Scand 1991; 83: 250–3PubMedCrossRef
118.
go back to reference Zeitlhofer J, Doppelbauer A, Tribl G, et al. Changes of serum lipid patterns during long-term anticonvulsive treatment. Clin Invest 1993; 71: 574–8CrossRef Zeitlhofer J, Doppelbauer A, Tribl G, et al. Changes of serum lipid patterns during long-term anticonvulsive treatment. Clin Invest 1993; 71: 574–8CrossRef
119.
go back to reference Sudhop T, Bauer J, Elger CE, et al. Increased high-density lipoprotein cholesterol in patients with epilepsy treated with carbamazepine: a gender-related study. Epilepsia 1999; 40: 480–4PubMedCrossRef Sudhop T, Bauer J, Elger CE, et al. Increased high-density lipoprotein cholesterol in patients with epilepsy treated with carbamazepine: a gender-related study. Epilepsia 1999; 40: 480–4PubMedCrossRef
120.
go back to reference Heldenberg D, Harel S, Holtzman M, et al. The effect of chronic anticonvulsant therapy on serum lipids and lipoproteins in epileptic children. Neurology 1983; 33: 510–3PubMedCrossRef Heldenberg D, Harel S, Holtzman M, et al. The effect of chronic anticonvulsant therapy on serum lipids and lipoproteins in epileptic children. Neurology 1983; 33: 510–3PubMedCrossRef
121.
go back to reference Reddy MN. Effect of anticonvulsant drugs on plasma total cholesterol, high-density lipoprotein cholesterol, and apolipoproteins A and B in children with epilepsy. Proc Soc Exp Biol Med 1985; 180: 359–63PubMed Reddy MN. Effect of anticonvulsant drugs on plasma total cholesterol, high-density lipoprotein cholesterol, and apolipoproteins A and B in children with epilepsy. Proc Soc Exp Biol Med 1985; 180: 359–63PubMed
122.
go back to reference Franzoni E, Govoni M, D’Addato S, et al. Total cholesterol, high-density lipoprotein cholesterol, and triglycerides in children receiving antiepileptic drugs. Epilepsia 1992; 33: 932–5PubMedCrossRef Franzoni E, Govoni M, D’Addato S, et al. Total cholesterol, high-density lipoprotein cholesterol, and triglycerides in children receiving antiepileptic drugs. Epilepsia 1992; 33: 932–5PubMedCrossRef
123.
go back to reference Eiris JM, Lojo S, Del Rio MC, et al. Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology 1995; 45: 1155–7PubMedCrossRef Eiris JM, Lojo S, Del Rio MC, et al. Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology 1995; 45: 1155–7PubMedCrossRef
124.
go back to reference Muuronen A, Kaste M, Nikkila EA, et al. Mortality from ischaemic heart disease among patients using anticonvulsive drugs: a case-control study. Br Med J Clin Res Ed 1985; 291: 1481–3PubMedCrossRef Muuronen A, Kaste M, Nikkila EA, et al. Mortality from ischaemic heart disease among patients using anticonvulsive drugs: a case-control study. Br Med J Clin Res Ed 1985; 291: 1481–3PubMedCrossRef
125.
go back to reference Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823–8PubMedCrossRef Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823–8PubMedCrossRef
126.
go back to reference Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751–6PubMedCrossRef Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751–6PubMedCrossRef
127.
go back to reference Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6PubMedCrossRef Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6PubMedCrossRef
Metadata
Title
Drug-Induced Lipid Changes
A Review of the Unintended Effects of Some Commonly Used Drugs on Serum Lipid Levels
Authors
Dr Aukje K. Mantel-Teeuwisse
Judith M.E. Kloosterman
Anke Hilse Maitland- van der Zee
Olaf H. Klungel
Arijan J. Porsius
Anthonius de Boer
Publication date
01-05-2001
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 6/2001
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200124060-00003

Other articles of this Issue 6/2001

Drug Safety 6/2001 Go to the issue